Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study
Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) need to be clarified. Experimental Design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germ line mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients, respectively. RETM918T was the most common somatic RET mutation (n = 75). RET somatic mutations were associated with male sex, larger tumor size, advanced American Joint Committee Cancer (AJCC) stage, vascular invasion, and high International Medullary Thyroid Carcinoma Grading System (IMTCGS) grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (eighth edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germ line mutations were significantly associated with reduced distant metastasis-free survival on univariate analysis, but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germ line mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall survival (OS) and disease-specific survival (DSS), independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage. RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased OS and DSS in MTC, but its prognostic value needs to be confirmed in future studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Thyroid : official journal of the American Thyroid Association - 34(2024), 2 vom: 25. Feb., Seite 167-176 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.10.1 |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 25.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/thy.2023.0279 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36335655X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36335655X | ||
| 003 | DE-627 | ||
| 005 | 20240229151457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/thy.2023.0279 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1305.xml |
| 035 | |a (DE-627)NLM36335655X | ||
| 035 | |a (NLM)37842841 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Bin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) need to be clarified. Experimental Design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germ line mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients, respectively. RETM918T was the most common somatic RET mutation (n = 75). RET somatic mutations were associated with male sex, larger tumor size, advanced American Joint Committee Cancer (AJCC) stage, vascular invasion, and high International Medullary Thyroid Carcinoma Grading System (IMTCGS) grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (eighth edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germ line mutations were significantly associated with reduced distant metastasis-free survival on univariate analysis, but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germ line mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall survival (OS) and disease-specific survival (DSS), independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage. RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased OS and DSS in MTC, but its prognostic value needs to be confirmed in future studies | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RAS | |
| 650 | 4 | |a RET | |
| 650 | 4 | |a grade | |
| 650 | 4 | |a medullary thyroid carcinoma | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Viswanathan, Kartik |e verfasserin |4 aut | |
| 700 | 1 | |a Ahadi, Mahsa S |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Alzumaili, Bayan |e verfasserin |4 aut | |
| 700 | 1 | |a Bani, Mohamed-Amine |e verfasserin |4 aut | |
| 700 | 1 | |a Baudin, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Behrman, David Blake |e verfasserin |4 aut | |
| 700 | 1 | |a Capelletti, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Chau, Nicole G |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarucci, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Clifton-Bligh, Roderick |e verfasserin |4 aut | |
| 700 | 1 | |a Coluccelli, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a de Biase, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a De Leo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Dogan, Snjezana |e verfasserin |4 aut | |
| 700 | 1 | |a Fagin, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Talia L |e verfasserin |4 aut | |
| 700 | 1 | |a Glover, Anthony Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Hadoux, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Lacroix, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Lamartina, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Lubin, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Luxford, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Magliocca, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Maloberti, Thais |e verfasserin |4 aut | |
| 700 | 1 | |a Mohanty, Abhinita S |e verfasserin |4 aut | |
| 700 | 1 | |a Najdawi, Fedaa |e verfasserin |4 aut | |
| 700 | 1 | |a Nigam, Aradhya |e verfasserin |4 aut | |
| 700 | 1 | |a Papachristos, Alexander James |e verfasserin |4 aut | |
| 700 | 1 | |a Repaci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Scoazec, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Qiuying |e verfasserin |4 aut | |
| 700 | 1 | |a Sidhu, Stan |e verfasserin |4 aut | |
| 700 | 1 | |a Solaroli, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Sywak, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Tuttle, R Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Untch, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Barletta, Justine A |e verfasserin |4 aut | |
| 700 | 1 | |a Al Ghuzlan, Abir |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Anthony J |e verfasserin |4 aut | |
| 700 | 1 | |a Ghossein, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Tallini, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ganly, Ian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thyroid : official journal of the American Thyroid Association |d 1990 |g 34(2024), 2 vom: 25. Feb., Seite 167-176 |w (DE-627)NLM013075799 |x 1557-9077 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2024 |g number:2 |g day:25 |g month:02 |g pages:167-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/thy.2023.0279 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2024 |e 2 |b 25 |c 02 |h 167-176 | ||